Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 20, 2025Tumori Journal

Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica

View Full Paper
Ask AI
Bookmark
Share

Authors

AVAnna Amela ValsecchiMSMatilde ScaldaferriMTMarcello Tiseo

Discussion

Loading...

Member takes

Overview

Observational analysis showed significant inter-hospital variability in off-label cancer drug evaluations, indicating potential disparities in patient access to care.

Key Points

  • Significant inter-hospital variability exists in the approval process for off-label cancer drugs, affecting patient access.
  • Mean approval rate across centers for individual requests was 76.6%, highlighting disparities in evaluations.
  • Inter-rater agreement was poor, with a Fleiss’ kappa of 0.009, suggesting inconsistency among centers' decisions.
  • Requests based on retrospective studies and clinical trials had similar approval rates, emphasizing the variability in evaluation criteria.

Cite This Study

Valsecchi et al. (2025) studied this question.

synapsesocial.com/papers/68f58f68ece7a5b64f471603https://doi.org/10.1177/03008916251386285
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 15PSQ-033 Abstract withdrawn2024
  2. 22SPD-002 Evaluation of the effectiveness and related cost of oncology drugs used in special situations, in a third-level university hospital2024
  3. 3Discrepancies in therapeutic indications for the same oncology drugs among FDA, EMA, and Brazilian agency.2024
  4. 4Comparison of baseline patient characteristics in Italian oncology drug monitoring registries and clinical trials: a real-world cross-sectional study2024 · 4 citations
  5. 5MAP of molecular analyses in real-worlD oncology centers – MAPpaMoNDO: a study of the translational research Young GOIM group2026